Oximonitor

Project "Oximonitor" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Microcirculatory failure (the inability to deliver sufficient O2 to the cells of the body), is a symptom from several health conditions affecting millions of individuals worldwide (e.g. heart failure, neonatal asphyxia or sepsis). The societal and financial impact of these conditions is enormous, as exemplified by patients in need of cardiac and respiratory support (such as extracorporeal membrane oxygenation life support or ECMO), with only 17% of survivors, while costing up to 1.35 M€ for a 1-year treatment. Specialists cannot predict if these patients are clinically dead or can recover because available medical devices do not allow to monitoring patient´s microcirculatory function. To solve this, at ODI Medical (a Norwegian start-up company) we have developed OXIMONITOR, the first-ever proof-of-concept validated, patented and non-invasive point of care (POC) integrated platform used bedside that accurately monitors microcirculatory function by quantifying O2 delivery and allows to assess the effectiveness of the patient´s treatment of choice, all in a user-friendly manner. OXIMONITOR incorporates: (1) The mLab hardware which creates an “optical fingerprint” of the patient’s circulatory function by collecting data from the surface of the patient’s skin, the conjunctiva or even sublingually. (2) The cLab; a Cloud computing software based on machine learning technology that collects and analyses the data generating the patient´s interpretation report, which is sent back to the clinical site through a user-friendly dashboard for decision-making. The market of cardiac monitoring (our first clinical application) will reach €22 billion by 2022 at a CAGR of 3.9% (2017-2022). With OXIMONITOR we will contribute to the viability of our company, generating a cumulative profit of 34.39 M€ (ROI of 12.75) and growing our staff count 400% by 2023. Likewise, the IP generated by this project will allow us to expand the number of clinical applications using our platform.